Read more
8:27 PM · 2 April 2025

BREAKING: Novavax shares tumble as FDA misses deadline For Covid-19 vaccine approval

Novavax
Stocks
NVAX.US, Novavax Inc
-
-

The FDA has missed the deadline for making a key decision regarding a Novavax (NVAX.US) Covid-19 vaccine, days after the Food and Drug Administration’s vaccine chief was pushed out. Novavax’s application needed more data and was unlikely to be approved soon - was said by people familiar with a matter, citted by WSJ.

This information is seriously damaging the sentiment around the company and is undermining its current ability to maintain its business system. The shares are losing over 1.5%, although at one point the declines were as high as 4%.

 

Source: xStation 

17 December 2025, 9:19 PM

Oracle shares fall 6% amid fears of financial troubles 🔎

17 December 2025, 5:11 PM

Lennar dips 4.6% after publishing quarterly earnings💡

17 December 2025, 2:40 PM

DE40: Many informations, few movements

16 December 2025, 8:11 PM

From Euphoria to Correction: CoreWeave and the Future of AI Infrastructure

The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.

Join over 2 000 000 investors from around the world